Placebo matching lenvatinib — Competitive Intelligence Brief

Placebo matching lenvatinib (Placebo matching lenvatinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor. Area: Oncology.

phase 3 Multi-targeted tyrosine kinase inhibitor FGFR, VEGFR, RET, KIT Oncology Small molecule

Target snapshot

Placebo matching lenvatinib (Placebo matching lenvatinib) — Merck Sharp & Dohme LLC. Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks signaling pathways critical for tumor growth and angiogenesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo matching lenvatinib TARGET	Placebo matching lenvatinib	Merck Sharp & Dohme LLC	phase 3	Multi-targeted tyrosine kinase inhibitor	FGFR, VEGFR, RET, KIT
Lenvatinib plus TACE	Lenvatinib plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-targeted tyrosine kinase inhibitor (in combination with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT, and other receptor tyrosine kinases
Lenvatinib, sintilimab plus TACE	Lenvatinib, sintilimab plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor + PD-1 inhibitor + locoregional chemotherapy	FGFR, VEGFR, RET, KIT (lenvatinib); PD-1 (sintilimab)
Adjuvant tislelizumab plus lenvatinib	Adjuvant tislelizumab plus lenvatinib	Guangxi Medical University	phase 3	PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination	PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib)
DEB-TACE plus Lenvatinib	DEB-TACE plus Lenvatinib	Guangxi Medical University	phase 3	Combination therapy: locoregional chemotherapy + multi-kinase inhibitor	DEB-TACE: topoisomerase II (doxorubicin); Lenvatinib: FGFR, VEGFR, RET, KIT, PDGFR
Len-TACE	Len-TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor (combined with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT
Sunitinib Malate (SU011248)	Sunitinib Malate (SU011248)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
2. Exelixis · 2 drugs in this class
3. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National Cancer Institute, Naples · 1 drug in this class
6. Sponsor GmbH · 1 drug in this class
7. Sun Yat-sen University · 1 drug in this class
8. TransThera Sciences (Nanjing), Inc. · 1 drug in this class
9. Advenchen Laboratories Nanjing Ltd. · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class